Peptic Ulcers Market

Market Overview:

The 7 major peptic ulcers markets reached a value of US$ 4.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 6.1 Billion by 2034, exhibiting a growth rate (CAGR) of 2.65% during 2024-2034.

The peptic ulcers market has been comprehensively analyzed in IMARC's new report titled "Peptic Ulcers Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peptic ulcers refer to open sores that occur in the lining of the stomach, upper small intestine (duodenum), or esophagus. They develop when the protective layer of mucus that normally lines these organs is eroded, exposing the underlying tissues to the corrosive effects of stomach acid and digestive juices. Peptic ulcers are often characterized by various symptoms, such as abdominal pain or discomfort, typically in the upper abdomen, which may be described as a burning or gnawing sensation. Several other common indications include nausea, vomiting, loss of appetite, unintentional weight loss, bloating, a feeling of fullness, etc. In some cases, peptic ulcers can cause bleeding, leading to the presence of blood in the stool or black, tarry stools. The diagnosis of peptic ulcers involves a comprehensive evaluation by a healthcare professional. Numerous diagnostic tests may include an upper endoscopy, which allows direct visualization of the stomach and duodenum, enabling the identification of ulcers and the collection of tissue samples for biopsy. Various other procedures, such as blood tests to detect H. pylori infection and imaging studies like an upper gastrointestinal series or abdominal ultrasound, etc., may also be performed to aid in the diagnosis.

The increasing cases of Helicobacter pylori (H. pylori) infection that can weaken the protective lining of the stomach and duodenum, thereby allowing stomach acid to damage the underlying tissues and form ulcers, are primarily driving the peptic ulcers market. Apart from this, the rising incidences of various associated risk factors, including prolonged use of nonsteroidal anti-inflammatory drugs, heavy alcohol consumption, chronic stress, etc., are also bolstering the market growth. Furthermore, the widespread adoption of proton pump inhibitors (PPIs), such as omeprazole, esomeprazole, pantoprazole, etc., to reduce the production of stomach acid while promoting ulcer healing and symptom relief is creating a positive outlook for the market. Besides this, the escalating utilization of mucosal protective agents for treating the condition, since they promote the secretion of protective mucus as well as stimulate mucosal blood flow, is also augmenting the market growth. Additionally, the emerging popularity of precision antibiotic therapy, which aims to customize the antibiotic regimen based on the susceptibility profile of the infecting H. pylori strain, thereby improving eradication rates and reducing the risk of antibiotic resistance, is expected to drive the peptic ulcers market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the peptic ulcers market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peptic ulcers and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peptic ulcers market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the peptic ulcers market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the peptic ulcers market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current peptic ulcers marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the peptic ulcers market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the peptic ulcers market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the peptic ulcers market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of peptic ulcers across the seven major markets?
• What is the number of prevalent cases (2018-2034) of peptic ulcers by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of peptic ulcers by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of peptic ulcers by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with peptic ulcers across the seven major markets?
• What is the size of the peptic ulcers patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of peptic ulcers?
• What will be the growth rate of patients across the seven major markets?
   

Peptic Ulcers: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for peptic ulcers drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peptic ulcers market?
• What are the key regulatory events related to the peptic ulcers market?
• What is the structure of clinical trial landscape by status related to the peptic ulcers market?
• What is the structure of clinical trial landscape by phase related to the peptic ulcers market?
• What is the structure of clinical trial landscape by route of administration related to the peptic ulcers market?